Core Viewpoint - The company announced that its wholly-owned subsidiary, Nanjing Ximosebo Testing Technology Co., Ltd., has received the High-tech Enterprise Certificate, which will provide significant tax benefits for the next three years [1] Group 1: Company Announcement - Nanjing Ximosebo has been recognized as a high-tech enterprise for the third time, with the certificate issued on December 19, 2025, and valid for three years [1] - The company will benefit from a reduced corporate income tax rate of 15% from January 1, 2025, through 2027, in accordance with relevant tax policies for high-tech enterprises [1]

Core Viewpoint - Baihua Pharmaceutical's subsidiary, Nanjing Ximosi Bo Testing Technology Co., Ltd., has been recognized as a high-tech enterprise for the third time by the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the State Taxation Administration of Jiangsu Province [2] Group 1 - The recognition as a high-tech enterprise indicates the company's commitment to innovation and technology development [2] - This certification may enhance the company's reputation and potentially lead to increased funding opportunities and tax benefits [2] - The repeated recognition reflects the company's sustained performance and capabilities in the high-tech sector [2]

Core Viewpoint - Baohua Pharmaceutical (600721.SH) announced that its wholly-owned subsidiary, Nanjing Simasibo Testing Technology Co., Ltd. (referred to as "Simasibo"), received the "High-tech Enterprise Certificate" from the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the State Taxation Administration of Jiangsu Province, valid for three years [1] Group 1 - Simasibo has been recognized as a high-tech enterprise for the third time [1] - The certificate was issued on December 19, 2025, with a validity period until December 19, 2028 [1]

Core Viewpoint - Longshen Rongfa's subsidiary, Gansu Pharmaceutical Group Guofang Testing Co., Ltd., has received the CNAS laboratory accreditation certificate, indicating recognition of its management and technical capabilities at both national and international levels, which is expected to positively impact the company's future operations [1] Group 1 - The CNAS laboratory accreditation certificate signifies that Guofang Testing's laboratory management and technical capabilities have been recognized [1] - The acquisition of the certificate is anticipated to have a positive effect on the company's future business operations [1] - The certificate's attainment will not have a significant impact on the company's current operating performance [1]